Kornimate/medical-research-clean huggingface dataset:
assessment of infrared photobiotherapy for improved wound healing

Conditions: Wound Healing

Summary: the purpose of this study is to examine whether or not low level laser therapy (lllt) can reduce pain and/or improve wound healing in patients with an acute traumatic injury to the upper extremity (wrist, forearm, or elbow).

this is a prospective, two group, controlled study using random assignment. all eligible patients will be randomly assigned to one of two groups: the control group (usual care) or the experimental group (usual care plus lllt). we plan to enroll 50 subjects in this study: 25 subjects will be randomly assigned to the lllt group and 25 to the usual care group. all subjects will be recruited within one to two days prior to hospital discharge or at the time of their first postoperative clinic visit. no subjects will be recruited while sedated or receiving intravenous pain medication.

Eligibility criteria:
inclusion criteria: * age \> 18 and \< 85 years * acute traumatic injury of an upper extremity (wrist, forearm, or elbow) * currently resides within 100 miles of umc exclusion criteria: * pregnant * pacemaker * medications that have heat or light-sensitivity contraindications (such as: steroids, some antibiotics) * two or more cardiac risk factors * intraoperative complications * wound infection * open wound
ten years results of a score system to address adjuvant therapies after breast conserving surgery for ductal carcinoma in situ of the breast

Conditions: Carcinoma Breast

Summary: by this non-randomized prospective study, it's evaluated the outcome of patients underwent bcs for dcis at whom an established score system to address adjuvant therapies have been prospectively applied, according to the wideness of free margins. between march 2000 and april 2006, 224 patients were enrolled and followed within the study.


Eligibility criteria:
inclusion criteria: * age \>18 years; * female candidate to breast conservative surgery exclusion criteria: * female with previous omolateral or controlateral breast cancer; * female with previous radiotherapy (rt).
performance of the tasman continuous positive airway pressure (cpap) system

Conditions: Obstructive Sleep Apnea

Summary: assessment of the performance of the tasman cpap system in treating obstructive sleep apnea. the purpose of this study is to (1) evaluate the performance of this system in the efficacy of the treatment in comparison to s8 escape, and (2) to evaluate the performance of the tasman device via subjective assessment of comfort and ease of breathing compared to the participant's current cpap device.

obstructive sleep apnoea (osa) is a condition characterised by partial or complete collapse of the upper airway during sleep. the treatment of choice for osa is continuous positive airway pressure (cpap). cpap acts as a positive airway splint, delivering a fixed positive airway pressure to the upper airway via a tube and mask. the mask is attached to the participant's nose via head straps. the type of mask used is dependent upon participant choice and comfort and the mask that provides the best fit. some participants stop using cpap therapy finding it difficult to tolerate due to leak issues or discomfort from their nasal mask. another frequent concern is mask dislodgment while sleeping causing leaks and consequently waking the patient up. the purpose of this study is to evaluate the performance of the tasman cpap system via objective and subjective assessment of comfort and ease of breathing compared to the participant's current cpap device. aim * to determine if the efficacy of the treatment is clinically equivalent to or better than the predicate device (s8 escape) * to evaluate the performance of the tasman cpap system in terms of comfort of breathing and general ease of use

Eligibility criteria:
inclusion criteria * patients willing to give written informed consent * patients who can read and comprehend english * patients being treated for osa for \>6 months * patients using a resmed nasal mask system * patients who can trial the trial mask for 7 nights exclusion criteria * patients not willing to give written informed consent * patients who can not read and comprehend english * patients being treated for osa for \<6 months * patients using an inappropriate mask system * patients using bilevel flow generators * patients who are not using cpap between 7 and 13 cmh2o * patients who are pregnant * patients who cannot trial the trial mask for 7 nights * patients with a hearing impairment
effects of long-term exercise on various parameters in heavy drinkers

Conditions: Heavy Drinking; Alcohol Abuse; Alcohol Use Disorder

Summary: the purpose of this research is to examine the effects of long-term aerobic exercise of moderate intensity on psychological, physiological, biochemical, physiological and alcohol-related parameters in heavy drinkers, in order to investigate possible biochemical mechanisms by which exercise may be a healthy alternative to alcohol abuse.

the mechanism of incentives that lead people to unhealthy habits such as excessive alcohol consumption is not only social, personal, and psychological, but also associated with neurochemical and neurobiological mechanisms. several programs have been developed to stop excessive drinking, but the success rates are small, while the relapse rates are very high, reaching up to 90%. although there is some evidence for the beneficial effects of exercise on alcohol use disorders, research is limited. the present study investigates whether exercise can act as adjunct therapy for alcohol abuse cessation. one of the basic assumptions is that the appropriate form of exercise in alcoholics will contribute to the secretion of beta-endorphin, which in combination with psychological pleasure, vitality, change of mood, reduced stress, increased confidence, and the shift of attention will help people to follow healthy lifestyles and abhor alcohol. the research project is divided in three phases. in the first phase, the effect of acute exercise in critical psychological, physiological, biochemical and alcohol-related parameters associated with excessive alcohol consumption will be examined. in the second phase (current study), a long-term exercise program in conjunction with psychological support strategies aimed at alcohol abuse cessation will be developed, implemented and evaluated. finally, in the third phase, based on the results of the previous phases, awareness programs in adolescent and adult populations will be designed and implemented as well as the dissemination of results and evaluation of the project will take place.

Eligibility criteria:
inclusion criteria: * men drinking \>14 drinks/week or \>4 drinks/occasion; women drinking \>7 drinks/week or \>4 drinks/occasion (1 drink = 14 grams of pure alcohol; definition of the niaaa for drinking at low risk for developing an aud; niaaa, 2014) * individuals drinking 5 or more drinks on the same occasion on each of 5 or more days in the past 30 days (1 drink = 14 grams of pure alcohol; definition of the substance abuse and mental health services administration for heavy drinking; niaaa, 2014) alcohol use disorders identification test (audit) score\>8 exclusion criteria: * medical conditions or medication use that would preclude participation in aerobic exercise

Keywords: heavy drinking heavy drinking cessation alcohol abuse alcohol use disorder
treatment continuation study for patients with als/mnd who completed study cmd-2019-001

Conditions: Amyotrophic Lateral Sclerosis

Summary: provides up to six months treatment with cuatsm for subjects who have successfully completed study cmd-2019-001

provides up to six months treatment with cuatsm for subjects who have successffulyl completed study cmd-2019-001. \[this allows subjects randomized to placebo on study cmd-2019-001 to receive up to six months treatment with cuatsm and provides an up to an additional six months treatment with cuatsm for subjects randomized to cuatsm on study cmd-2019-001\]

Eligibility criteria:
inclusion criteria: * signed informed consent prior to initiation of any study-specific procedures and treatment * documented completion of protocol-specified assessments following completion of 24 weeks treatment on study cmd-2019-002 * investigator considers patient has been tolerating treatment on study cmd-2019-001 and may benefit from continued treatment with cuatsm exclusion criteria: * not dependent on mechanical ventilation
effect of brain lesion severity on treatment response in late-life depression

Conditions: Depression

Summary: this study will determine the relationship between brain lesion severity, treatment response, and frontal lobe brain function in people with late-life depression (lld).

depression in older adults is a major public health problem and it often goes underdiagnosed and undertreated. a significant number of people with lld, especially those with cerebrovascular risk factors, have subcortical grey matter and frontal deep white matter brain lesions. some studies suggest that these lesions, or hyperintensities, may be associated with poor acute and long-term depression treatment response. similarly, studies have shown that people with lld frequently have functional deficits in the frontal lobe portion of their brains. this dysfunction has been shown to be associated with poor acute treatment response with a tricyclic antidepressant drug, as well as with a greater risk for depression relapse. the applicability of these findings to other classes of antidepressant medications, such as selective serotonin reuptake inhibitors (ssris), however, remains unknown. additionally, more information is needed about the interaction between frontal brain lesions and executive function deficits in lld. this study will determine the relationship between brain lesion severity, treatment response, and frontal lobe function in people with late-life depression who are being treated with the ssri sertraline. participants in this open label study will first undergo neuropsychological testing to determine eligibility. all eligible participants will be treated with sertraline for 12 weeks. dosages will begin at 25 mg per day, and will be increased to 50 mg per day after 4 days. any other dosage modifications will depend on the participant's individual response to the medication. all participants will have an mri scan at some point during the study. assessments of symptoms and treatment response will occur at the study site biweekly until week 8, and then again at week 12.

Eligibility criteria:
inclusion criteria: * dsm-iv of major depressive disorder (mdd) * score of greater than 20 on the madrs (score of greater than 17 for atypical depression) * score of greater than 20 on the mini mental state examination (mmse) exclusion criteria: * any condition that may make having an mri medically inadvisable * any severe or unstable medical conditions * any known primary neurological disorders, including history of stroke * any other simultaneous axis i disorder * history of substance or alcohol abuse disorder within 6 months prior to study entry * currently at risk for suicide * history of failed prior adequate trials of two antidepressants for the current depressive episode * history of failed prior adequate trial of sertraline * current use of any other psychoactive medications (medication washout will be required)

Keywords: late-life depression
safety and tolerability study of aripiprazole im depot in adult subjects with schizophrenia

Conditions: Schizophrenia; Mental Disorder; Nervous System Diseases

Summary: to determine the safety and tolerability of multiple-dose administrations of aripiprazole intramuscular (im) depot in the deltoid muscle in adult subjects with schizophrenia

this is a trial designed to assess the safety and tolerability of multiple-dose administrations of aripiprazole intramuscular (im) depot in the deltoid muscle in adult subjects with schizophrenia. the trial consists of a 113 day treatment period with a 28 day followup. the trial population will include male and female subjects between 18 and 64 years (inclusive), with a current diagnosis of schizophrenia as defined by dsm-iv-tr criteria and a prior history of tolerating aripiprazole per investigator's judgement.

Eligibility criteria:
inclusion criteria: * male and female individuals between 18 and 64 years, inclusive, at the time of informed consent. * prior history of tolerating aripiprazole per investigator's judgement. exclusion criteria: * subjects who have met dsmv-iv-tr criteria for substance dependence within the past 180 days. * subjects who use more than one antipsychotic medication at screening. * use of any cyp2d6 and cyp3a4 inhibitors, or cyp3a4 inducers within 14 days prior to dosing and for the duration of the trial. * subjects who participated in any clinical trial involving a psychotropic medication within 1 month prior to enrollment. * subjects currently in an acute relapse of schizophrenia. * subjects with a current dsmv-iv-tr diagnosis other than schizophrenia. * subjects who are considered treatment-resistant to antipsychotic medications.

Keywords: opc-14597 aripiprazole schizophrenia
ultrasound-guided thermal ablation for recurrent thyroid cancer

Conditions: Recurrent Thyroid Cancer

Summary: to evaluate the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer

to evaluate and predict the long-term outcomes of ultrasound-guided thermal ablation for recurrent thyroid cancer by a multicenter study

Eligibility criteria:
inclusion criteria: 1. patient received thyroidectomy for thyroid cancer 2. recurrent lesions were pathologically proven to be malignant by core-needle biopsy or fine needle aspiration 3. no evidence of distant metastases. 4. follow-up period ≥12 months exclusion criteria: 1. coagulation disorder, serious heart, respiratory, liver, or renal failure 2. dysfunction of the vocal cord on the opposite side
treatment for knee osteoarthritis with injections of bmc at the bone-cartilage interface. pilot study

Conditions: Knee Osteoarthritis

Summary: this pilot study will evaluate the clinica! and radiological results of a treatment for knee osteoarthritis with injections of autologous concentrated bone marrow aspirate at the bone-cartilage interface via percutaneous.

this pilot study (n=30) patients will evaluate the clinica! and radiological results of a treatment for knee osteoarthritis with injections of bone marrow concentrate (bmc),obtained from the bone marrow aspirate concentration system (biocue) at the bone-cartilage interface via percutaneous injections. the perfuse system will also be evaluated to determine if it can be used to deliver the bmc to the osseous sites. follow-up is 1, 3, 6, 12, and 24 months.

Eligibility criteria:
inclusion criteria: * age ranging from 40 to 75 * osteoarthritis of the medial or lateral compartment (2-3-4 grade according to the kellgren-lawrence score); * failure after at least 6 months of conservative treatment (drug therapy with nsaids,hyaluronic acid,platelet-rich plasma and corticosteroids injections); * signature of informed consent. exclusion criteria: * patients with trauma in the 6 months prior to the intervention; * patients with malignancies; * patients with rheumatic diseases; * patients with diabetes; * patients suffering from metabolic disorders of the thyroid; * patients being abuse of alcohol, drugs or medications; * body mass index\> 35;

Keywords: knee osteoarthritis , bone marrow aspirate injections
comparing hepes-buffered with bicarbonate-buffered as handling media during the icsi procedure on live birth rate

Conditions: Infertility

Summary: the ph stability during human gamete handling for intracytoplasmic sperm injection (icsi) is physiologically sound. as the ph change for bicarbonate-buffered medium, scientists assumed whether the use of hepes or mops buffered medium would provide more stable ph, thereby better outcomes. however, the oil use and time frame outside the incubators have not been accounted for. this study is to evaluate the use of hepes buffered medium compared with the bicarbonate-buffered medium on icsi outcomes.


Eligibility criteria:
inclusion criteria: * icsi indicated cycles exclusion criteria: * severe medical illness
pancreatoduodenectomy with or without ligamentum teres wrap around gastroduodenal artery stump for prevention of pancreatic hemorrhage

Conditions: Pancreatoduodenectomy

Summary: to investigate, whether a prophylactic wrapping of the gastroduodenal artery stump with the ligamentum teres or falciform hepatic (embryological structures, covered with peritoneum that do not have relevant meaning for adults) can reduce the incidence of arrosion bleeding during surgery. thus a surgical technique is evaluated prospectively.

pancreatoduodenectomy is a standard surgical procedure for resection of tumors of the pancreatic head and neck, and for selected patients with chronic pancreatitis. a postoperative pancreatic fistula (popf) is a severe and frequent complication that may lead to a potentially letal arrosion hemorrhage from the stump of the gastroduodenal artery (gda). aim of the study is to evaluate the prophylactic wrapping of the gda stump using the falciform hepatic ligament during the index operation. the null hypothesis is that prophylactic wrapping does not decrease the incidence of arrosion hemorrhage from the gda stump. the study is designed as a randomized, single-blinded, controlled, multicenter trial.

Eligibility criteria:
inclusion criteria: * indication for elective open pancreatoduodenectomy (pylorus-preserving or classic) with pancreatojejunostomy for tumors, or cystic lesions of the pancreatic head, tumors of the distal bile duct, duodenum or for chronic pancreatitis * american society of anesthesiologists classification i-iii * age ≥18 years * given informed consent exclusion criteria: * status post previous abdominal surgery with resection of the falciform ligament (e.g. hemihepatectomy) * no reconstruction using a pancreatojejunostomy (e.g. pancreatogastrostomy) * simultaneous visceral arterial resection
s-1/oxaliplatin for high risk patients who underwent gastrectomy

Conditions: Stomach Cancer

Summary: after curative resection, patients with stage iiib-iv (m0) gastric cancer were given chemotherapy as follows: s-1 orally at 80 mg/m2 divided in two daily doses for 14 days and oxaliplatin at 130 mg/m2 intravenously over 2 h every 21 days as one cycle. s1 was administered for 16 cycles (12 months) and oxaliplatin for 8 cycles (6 months).


Eligibility criteria:
inclusion criteria: * patients who voluntarily provide written informed consent prior to entering into this study * newly definitely diagnosed with primary gastric or gastroesophageal junction adenocarcinoma histologically * patients who underwent radical resection with wide lymph node dissection * tnm stage (6th ajcc) of iiib or iv on post-operative staging * patients who can be randomized within 6 weeks after surgery exclusion criteria: * aged \< 20 years or ≥ 76 years * eastern cooperative oncology group (ecog) performance status \>2 * patients who underwent surgery for neoplasm in stomach in the past * history of malignant disease the following cases can be included in this study - adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ * gastric or gastroesophageal junction adenocarcinoma with distant metastasis (m1) including distant lymph node (behind the pancreas, along the aorta, portal vein, behind the peritoneum, mesenteric lymph node) * residual cancer on post-operative staging (r1 and r2 resection) * patients who received adjuvant chemotherapy, or neoadjuvant chemotherapy and/or radiotherapy and/or immunotherapy in the past for treatment of gastric cancer * any of the following within 6 months prior to the study recruitment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass, nyha class iii or iv congestive heart failure, stroke or transient ischemic attack, serious cardiac arrhythmia requiring treatment * patients of childbearing potential who do not agree to use generally accepted effective method of birth control during the study treatment period and for at least 6 months after the end of study treatment * pregnant women, breastfeeding women, or women of childbearing potential whose pregnancy test result is positive• * history of hypersensitivity to the investigational products (s1 and oxaliplatin)

Keywords: stomach cancer
sleep apnea in lung cancer: a prospective study

Conditions: Lung Cancer; Sleep-Disordered Breathing

Summary: the study seeks to determine the prevalence of sleep disordered breathing in a population of patients diagnosed with lung cáncer.

obstructive sleep apnea hypopnea syndrome (osahs) is an important medical condition which causes significant morbidity and mortality. the prevalence of osahs in spain is 4-6% in men and 2-4% in women and rises steadily with age. snoring and smoking have been independently linked, and smoking may be a risk factor for developing osahs. this is particularly true of heavy smokers (\> 2 packs/day), those at greatest risk for lc. associations between osahs and some forms of cancer have been described in humans, especially in those experiencing nocturnal hypoxemia, and intermittent hypoxia has been linked to the progression of cancer in animal models. lc is currently the leading cause of cancer deaths in developped nations. a link between osahs and lc, therefore, is plausible. sleep disordered breathing may be common among patients recently diagnosed of lung cancer and may contribute to tumor progression. objectives: a) to perform home sleep testing in patients recently diagnosed with lung cancer in order to determine the prevalence of sleep disordered breathing in this patient population. b) to include biological samples obtained from all participants, including surgically treated patients with stage i / iip lc through the program in the ciberes pulmonary biobank platform. biological samples will be preserved under different storage conditions for subsequent determination of molecular biomarkers. c) to follow-up lung cancer patients with and without sleep disordered breathing in order to determine the potential influence osahs might have on their prognosis. prospective screening for sleep disordered breathing will be performed by home sleep testing in 100 subjects diagnosed with lung cancer, irrespective of stage at diagnosis, who give their consent. a modified epidemiologic questionnaire for sleep disordered breathing will also be administered. patients identified as suffering from osahs will be referred to sleep clinic. biologic samples and lung function studies will be obtained in all participating patients. all patients with lung cancer will undergo follow-up for at least three years or until their demise, and those identified with osahs will also be followed in sleep clinic. the prevalence of osahs in this patient population will be determined. a link between osahs, and especially intermittent nocturnal hypoxemia, and tumor progression will be sought.

Eligibility criteria:
inclusion criteria: * all patients with recently diagnosed lung cancer, inlcuding all stages of disease. exclusion criteria: * patients unable to comply with home sleep testing.

Keywords: lung cancer sleep apnea sleep disordered breathing